<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:mp ids='MP_0004024'>Aneuploidy</z:mp> is associated with poor prognosis in <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Spontaneous chromosome missegregation events in aneuploid cells promote <z:mp ids='MP_0008866'>chromosomal instability</z:mp> (CIN) that may contribute to the acquisition of multidrug resistance in vitro and heighten risk for <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> relapse in animal models </plain></SENT>
<SENT sid="2" pm="."><plain>Identification of distinct therapeutic agents that target <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> karyotypic complexity has important clinical implications </plain></SENT>
<SENT sid="3" pm="."><plain>To identify distinct therapeutic approaches to specifically limit the growth of CIN <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e>, we focused on a panel of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) cell lines, previously classified as either chromosomally unstable (CIN(+)) or diploid/near-diploid (CIN(-)), and treated them individually with a library of kinase inhibitors targeting components of signal transduction, cell cycle, and transmembrane receptor signaling pathways </plain></SENT>
<SENT sid="4" pm="."><plain>CIN(+) cell lines displayed significant intrinsic multidrug resistance compared with CIN(-) <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cell lines, and this seemed to be independent of <z:hpo ids='HP_0001428'>somatic mutation</z:hpo> status and proliferation rate </plain></SENT>
<SENT sid="5" pm="."><plain>Confirming the association of CIN rather than ploidy status with multidrug resistance, tetraploid isogenic cells that had arisen from diploid cell lines displayed lower drug sensitivity than their diploid parental cells only with increasing chromosomal <z:hpo ids='HP_0001425'>heterogeneity</z:hpo> and isogenic cell line models of CIN(+) displayed multidrug resistance relative to their CIN(-) parental <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cell line derivatives </plain></SENT>
<SENT sid="6" pm="."><plain>In a meta-analysis of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> outcome following cytotoxic treatment, CIN(+) predicted worse progression-free or disease-free survival relative to patients with CIN(-) disease </plain></SENT>
<SENT sid="7" pm="."><plain>Our results suggest that stratifying <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> responses according to CIN status should be considered within the context of clinical trials to minimize the confounding effects of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> CIN status on drug sensitivity </plain></SENT>
</text></document>